Search Results

Business

OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, today announced that the Company’s subsidiary mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureX’s mRNA technology.

June 15, 2022

·

2 min read

Policy

European Patent Office to Grant ToolGen, Inc. a patent on CRISPR-Cas9 system for genome editing

ToolGen, Inc. (KONEX 199800) announced today that on July 26, 2018 the European Patent Office (EPO) issued a Decision to Grant to ToolGen a European patent covering a CRISPR-Cas9 genome editing system adapted for mammalian cells.

August 6, 2018

·

3 min read

ToolGen Demonstrates Potential of CRISPR/cas9 Gene Editing to Overcome T-Cell Immunosuppressio

The study was presented in a poster presentation at the American Society of Hematology Annual Meeting.

December 11, 2017

·

2 min read

Business

Monsanto And ToolGen Announce Global Licensing Agreement On CRISPR Platform, Underscore The Benefits Of Innovation For Farmers

August 16, 2017

·

5 min read

Drug Development

ToolGen Highlights Study Results Demonstrating Utility Of AAV-Compatible Cas9 System In Vivo Genome Editing

February 22, 2017

·

3 min read

ToolGen Announces Poster Presentation On Genome Editing Of Human T Cells At 2017 American Society For Gene And Cell Therapy (ASGCT) Annual Meeting

May 16, 2017

·

2 min read

ToolGen Announces Poster Presentation On Genome Editing Of Human T Cells At 2017 American Society For Gene And Cell Therapy (ASGCT) Annual Meeting

May 15, 2017

·

2 min read

Illustration of a stack of paper and tweezers editing a strand of DNA in between two glass office buildings

CRISPR

Ongoing CRISPR Patent Dispute Complicates Licensing but Hasn’t Deterred Gene-Editing Investment

As the yearslong litigation over ownership of CRISPR gene editing continues, investors have forged ahead with funding the technology’s development by biopharma.

July 17, 2024

·

8 min read

·

Christoph Schwaiger

Business

Toolgen And Thermo Fisher Scientific Sign License Agreement For CRISPR/Cas9 Genome Editing Technology

March 10, 2015

·

4 min read

Biotech Beach

Thermo Fisher Scientific Expands Genome Editing IP Portfolio

Thermo Fisher Scientific, Inc., the world leader in serving science, has licensed CRISPR technologies from the Broad Institute and ERS Genomics (foundational University of California IP) to bolster its genome editing intellectual property (IP) portfolio.

September 18, 2018

·

2 min read